Infections in the first year of life and development of beta cell autoimmunity and clinical type 1 diabetes in high-risk individuals : the TRIGR cohort

Aims/hypothesis Accumulated data suggest that infections in early life contribute to the development of type 1 diabetes. Using data from the Trial to Reduce IDDM in the Genetically at Risk (TRIGR), we set out to assess whether children who later developed diabetes-related autoantibodies and/or clinical type 1 diabetes had different exposure to infections early in life compared with those who did not. Methods A cohort of 2159 children with an affected first-degree relative and HLA-conferred susceptibility to type 1 diabetes were recruited between 2002 and 2007 and followed until 2017. Infections were registered prospectively. The relationship between infections in the first year of life and the development of autoantibodies or clinical type 1 diabetes was analysed using univariable and multivariable Cox regression models. As this study was exploratory, no adjustment was made for multiple comparisons. Results Adjusting for HLA, sex, breastfeeding duration and birth order, those who had seven or more infections during their first year of life were more likely to develop at least one positive type 1 diabetes-related autoantibody (p=0.028, HR 9.166 [95% CI 1.277, 65.81]) compared with those who had no infections. Those who had their first viral infection aged between 6 and 12 months were less likely to develop at least one positive type 1 diabetes-related antibody (p=0.043, HR 0.828 [95% CI 0.690, 0.994]) or multiple antibodies (p=0.0351, HR 0.664 [95% CI 0.453, 0.972]). Those who had ever had an unspecified bacterial infection were more likely to develop at least one positive type 1 diabetes-related autoantibody (p=0.013, HR 1.412 [95% CI 1.075, 1.854]), to develop multiple antibodies (p=0.037, HR 1.652 [95% CI 1.030, 2.649]) and to develop clinical type 1 diabetes (p=0.011, HR 2.066 [95% CI 1.182, 3.613]). Conclusions/interpretation We found weak support for the assumption that viral infections early in life may initiate the autoimmune process or later development of type 1 diabetes. In contrast, certain bacterial infections appeared to increase the risk of both multiple autoantibodies and clinical type 1 diabetes.Peer reviewe

Pediatric obesity and skin disease: cutaneous findings and associated quality-of-life impairments in 103 children and adolescents with obesity

Objective: Little is known about specific cutaneous findings in children an d adolescents with overweight and obesity. This study assessed the association of skin signs with pivotal auxological and endocrinological parameters and their i nfluence on the quality of life (QoL) of young people with obesity. Study design: All patients initially recruited for a tertiary hospital's weight control program were offered participation in this interdisciplinary, single-center, cross-sectional study. All participants underwent a detailed dermatological examination, anthropometric measurements and laboratory examinations. QoL was assessed with validated questionnaires. Results: A total of 103 children and adolescents (age 11.6 ±2.5 years, 41% female, 25% prepubertal, BMI SDS 2.6 ± 0.5, homeostatic model assessment (HOMA) score 3.3 ± 4.2; mean ± s.d.) were recruited in a 12-month study period. Skin affections wer e linearly associated with increasing BMI and higher age. The most common skin findings were (%) striae distensae (71.0), keratosis pilaris (64.7), acanthosis nigricans (45.0), acne vulgaris (39.2), acrochordons (25.5) and plantar hyperkeratosis (17.6). The HOMA score was associated with acanthosis nigricans (P = 0.047), keratosis pilaris (P = 0.019) and acne vulgaris (P < 0.001). The general mean QoL(QoL) score, as assessed by the WHO-5, was 70 out of 100. A total of 38.9% of participants reported impaired dermatological QoL. Conclusions: This study shows the high prevalence of skin lesions in children and adolescents with obesity. The association between skin lesions and the HOMA score indicates that skin manifestations are a marker of insulin resistance. To prevent secondary diseases and improve QoL, thorough skin examinations and interdisciplinary cooperation are necessary

Criteria for Centers of Reference for pediatric diabetes--a European perspective

' SWEET' is an acronym standing for 'Better control in pediatric and adolescent diabeteS: Working to crEate CEnTers of Reference ( CORs)' and is based on a partnership of established national and European diabetes organizations such as International Diabetes Federation, Federation of European Nurses in Diabetes, and Primary Care Diabetes Europe (PCDE, www.sweet-project.eu). A three-level classification of centers has been put forward. In addition to centers for local care, SWEET collaborating centers on their way to being a COR have been defined. Peer-audited CORs with a continuous electronic documentation of at least 150 pediatric patients with diabetes treated by a multidisciplinary team based on the International Society for Pediatric and Adolescent Diabetes ( ISPAD) Clinical Practice recommendations have been created in 12 European countries. In 2011, they cared for between 150 to more than 700 youth with diabetes with an average hemoglobin A1c between 7.6 and 9.2%. Although these clinics should not be regarded as representative for the whole country, the acknowledgment as COR includes a common objective of targets and guidelines as well as recognition of expertise in treatment and education at the center. In a first step, the SWEET Online platform allows 12 countries using 11 languages to connect to one unified diabetes database. Aggregate data are de-identified and exported for longitudinal health and economic data analysis. Through their network, the CORs wish to obtain political influence on a national and international level and to facilitate dissemination of new approaches and techniques. The SWEET project hopes to extend from the initial group of centers within countries, throughout Europe, and beyond with the help of the ISPAD network

Screening for Type 1 Diabetes in the General Population:A Status Report and Perspective

Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living with the disease to improve yield and feasibility. However, ∼90% of those who develop type 1 diabetes do not have a family history. Recent successes in disease-modifying therapies to impact the course of early-stage disease have ignited the consideration of the need for and feasibility of population screening to identify those at increased risk. Existing population screening programs rely on genetic or autoantibody screening, and these have yielded significant information about disease progression and approaches for timing for screening in clinical practice. At the March 2021 Type 1 Diabetes TrialNet Steering Committee meeting, a session was held in which ongoing efforts for screening in the general population were discussed. This report reviews the background of these efforts and the details of those programs. Additionally, we present hurdles that need to be addressed for successful implementation of population screening and provide initial recommendations for individuals with positive screens so that standardized guidelines for monitoring and follow-up can be established

Consensus Recommendations for the Use of Automated Insulin Delivery (AID) Technologies in Clinical Practice

International audienceThe significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past six years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage

International Consensus on Use of Continuous Glucose Monitoring.

Measurement of glycated hemoglobin (HbA1c) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA1c testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes

Diagnostik und Management von primären und sekundären Komorbiditäten des Diabetes mellitus Typ 1 im Kindes- und Jugendalter

Ziel dieser Arbeit war es, in Querschnitts- und prospektiven Longitudinalstudien die Diagnostik diabetes-assoziierter Autoimmunerkrankungen (Autoimmun-Thyreoiditis und Zöliakie, primäre Komorbiditäten) sowie diagnostische Verfahren zur Früherkennung von sekundären Spätkomplikationen (Retinopathie und Nephropathie, sekundäre Komorbiditäten) bei Kindern und Jugendlichen mit Typ 1 Diabetes zu evaluieren. Mit Hilfe eines Screenings spezifischer Antikörper (EmA, IgA-Gliadin-, IgA-tTG-Antikörper) konnte eine höhere als bisher berichtete Zöliakie-Prävalenz bei zwei Prozent der asymptomatischen Kinder mit Typ 1 Diabetes festgestellt werden. Eine Autoimmun-Thyreoiditis wurde durch Untersuchungen von Schilddrüsen-spezifischen Antikörpern (Anti-TPO, Anti-TG) bei bis zu 20 Prozent der Kinder und Jugendlichen diagnostiziert. Mädchen hatten signifikant häufiger Schilddrüsen-Antikörper als Jungen. Mit zunehmendem Alter der Patienten stieg die Prävalenz der Antikörper. Die Anwesenheit positiver Schilddrüsen-Antikörper war mit höheren TSH-Werten assoziiert. Sehr hohe Schilddrüsen-Antikörper (Anti-TPO, Anti-TG) waren prädiktiv für die spätere Entwicklung einer subklinischen Hypothyreose. Hinsichtlich der sekundären Komorbiditäten konnte anhand von Messungen der glomerulären (Alb, Tf, IgG) und tubulären Marker (NAG, alpha1-MG) nachgewiesen werden, dass bei Patienten mit Diabetes nicht nur eine glomeruläre, sondern auch eine tubuläre renale Dysfunktion vorliegen kann. Eine erhöhte NAG-Urinausscheidung war prädiktiv für die Entwicklung einer Mikroalbuminurie. Für die Retinopathieentwicklung war die Stoffwechseleinstellung (HbA1c) von wesentlicher Bedeutung, insbesondere während der ersten Diabetesjahre. In der Pubertät kam es zu einer Beschleunigung der Retinopathieentwicklung. Weitere Risikofaktoren für sekundäre Spätkomplikationen insbesondere Retinopathie waren Blutdruck, Lipidstoffwechsel (Triglyzeride, HDL-Cholesterin) und Gesamtrenin. Für die Prognose und Prävention primärer und sekundärer Komorbiditäten bei Kindern mit einem Typ 1 Diabetes als chronische Grunderkrankung ist ein frühzeitiges und regelmäßiges Screening von wesentlicher Bedeutung.The aim of this study was the evaluation of diagnostic procedures for the early detection of diabetes-associated autoimmune diseases (autoimmune thyroiditis and coeliac disease, primary co-morbidity) as well as of diabetes-specific late complications (retinopathy and nephropathy, secondary co-morbidity) in children and adolescents with type 1 diabetes. The prevalence of coeliac disease among asymptomatic children with type 1 diabetes was 2 percent based on a screening for specific autoantibodies (EMA, IgA-gliadin-, IgA-tTG-antibodies) being higher than reported previously. Autoimmune thyroiditis was diagnosed in up to 20 percent of children and adolescents according to screening procedures for thyroid-specific antibodies (anti-TPO, anti-TG). Girls had more frequently thyroid antibodies than boys. The prevalence of thyroid antibodies increased with increasing age of patients. The presence of thyroid antibodies was associated with higher TSH values, while very high values of thyroid antibodies were predictive for the development of a subclinical hypothyroidism. Studies concerning the prevalence of secondary co-morbidity in young patients with type 1 diabetes revealed that not only glomerular, but also tubular renal dysfunction may occur in these patients. These studies based on the measurement of urinary excretion of glomerular (Alb, Tf, IgG) and tubular (NAG, alpha1-MG) markers. Elevated urinary excretion of NAG was predictive for the development of microalbuminuria. Glycaemic control (HbA1c), particularly during the first years of diabetes, constituted a significant parameter for the development of retinopathy, while puberty may accelerate the development of this late complication. Arterial blood pressure, lipid profile (triglycerides, HDL-cholesterol) and total renin had been found to be additional risk factors for the development of late complications, particularly retinopathy. An early and regularly performed screening is recommended for the prognosis and prevention of primary and secondary co-morbidity in children with type 1 diabetes

Association of diabetic ketoacidosis and HbA1c at onset with year-three HbA1c in children and adolescents with type 1 diabetes: Data from the International SWEET Registry

Piccini, Barbara/0000-0002-2684-8638; Kim, Jae Hyun/0000-0002-0203-7443; Jefferies, Craig/0000-0002-0541-6094; Schwandt, Anke/0000-0003-3041-0759WOS: 000503343500001PubMed: 31797499Objective To establish whether diabetic ketoacidosis (DKA) or HbA1c at onset is associated with year-three HbA1c in children with type 1 diabetes (T1D). Methods Children with T1D from the SWEET registry, diagnosed = 12%]). To adjust for demographics, linear regression was applied with interaction terms for DKA and HbA1c at onset groups (adjusted means with 95% CI). Association between year-three HbA1c and both HbA1c and presentation at onset was analyzed (Vuong test). Results Among 1420 children (54% males; median age at onset 9.1 years [Q1;Q3: 5.8;12.2]), 6% of children experienced DKA with coma, 37% DKA without coma, and 57% no DKA. Year-three HbA1c was lower in the low compared to high HbA1c at onset group, both in the DKA without coma (7.1% [6.8;7.4] vs 7.6% [7.5;7.8], P = .03) and in the no DKA group (7.4% [7.2;7.5] vs 7.8% [7.6;7.9], P = .01), without differences between low and medium HbA1c at onset groups. Year-three HbA1c did not differ among HbA1c at onset groups in the DKA with coma group. HbA1c at onset as an explanatory variable was more closely associated with year-three HbA1c compared to presentation at onset groups (P = .02). Conclusions Year-three HbA1c is more closely related to HbA1c than to DKA at onset; earlier hyperglycemia detection might be crucial to improving year-three HbA1c.Insulet; Sanofi; Medtronic EuropeMedtronic; Lilly Diabetes Excellence Centre; DexCom Inc.; AbbottAbbott Laboratories; Boehringer-IngelheimBoehringer IngelheimInsulet; Sanofi; Medtronic Europe; Lilly Diabetes Excellence Centre; DexCom Inc.; Boehringer-Ingelheim; Abbot